nevirapine has been researched along with Anemia in 16 studies
Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.
nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.
Anemia: A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (43.75) | 29.6817 |
| 2010's | 9 (56.25) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ogar, CK | 1 |
| Abiola, A | 1 |
| Yuah, D | 1 |
| Ibrahim, A | 1 |
| Oreagba, IA | 1 |
| Amadi, EC | 1 |
| Adeyeye, MC | 1 |
| Oshikoya, KA | 1 |
| Gedefaw, L | 1 |
| Yemane, T | 1 |
| Sahlemariam, Z | 1 |
| Yilma, D | 1 |
| Sartorius, BK | 1 |
| Chersich, MF | 1 |
| Mwaura, M | 1 |
| Meda, N | 1 |
| Temmerman, M | 1 |
| Newell, ML | 2 |
| Farley, TM | 1 |
| Luchters, S | 1 |
| Smith, C | 1 |
| Forster, JE | 1 |
| Levin, MJ | 1 |
| Davies, J | 1 |
| Pappas, J | 1 |
| Kinzie, K | 1 |
| Barr, E | 1 |
| Paul, S | 1 |
| McFarland, EJ | 1 |
| Weinberg, A | 1 |
| Rougemont, M | 1 |
| Nchotu Ngang, P | 1 |
| Stoll, B | 1 |
| Delhumeau, C | 1 |
| Hill, A | 1 |
| Ciaffi, L | 2 |
| Bonnet, F | 1 |
| Menga, G | 1 |
| Fampou, JC | 1 |
| Calmy, A | 2 |
| Naniche, D | 1 |
| Lahuerta, M | 1 |
| Bardaji, A | 1 |
| Sigauque, B | 1 |
| Romagosa, C | 1 |
| Berenguera, A | 1 |
| Mandomando, I | 1 |
| David, C | 1 |
| Sanz, S | 1 |
| Aponte, J | 1 |
| Ordi, J | 1 |
| Alonso, P | 1 |
| Menendez, C | 1 |
| Samuel, MI | 1 |
| Tenant-Flowers, M | 1 |
| Kumar, U | 1 |
| Taylor, C | 1 |
| Mugyenyi, P | 3 |
| Walker, AS | 2 |
| Hakim, J | 3 |
| Munderi, P | 2 |
| Gibb, DM | 2 |
| Kityo, C | 2 |
| Reid, A | 2 |
| Grosskurth, H | 3 |
| Darbyshire, JH | 3 |
| Ssali, F | 2 |
| Bray, D | 2 |
| Katabira, E | 3 |
| Babiker, AG | 1 |
| Gilks, CF | 1 |
| Kabuye, G | 1 |
| Nsibambi, D | 2 |
| Kasirye, R | 1 |
| Zalwango, E | 1 |
| Nakazibwe, M | 1 |
| Kikaire, B | 1 |
| Nassuna, G | 1 |
| Massa, R | 1 |
| Fadhiru, K | 2 |
| Namyalo, M | 1 |
| Zalwango, A | 1 |
| Generous, L | 1 |
| Khauka, P | 2 |
| Rutikarayo, N | 1 |
| Nakahima, W | 1 |
| Mugisha, A | 1 |
| Todd, J | 1 |
| Levin, J | 1 |
| Muyingo, S | 1 |
| Ruberantwari, A | 1 |
| Kaleebu, P | 2 |
| Yirrell, D | 2 |
| Ndembi, N | 2 |
| Lyagoba, F | 2 |
| Hughes, P | 1 |
| Aber, M | 1 |
| Lara, AM | 2 |
| Foster, S | 2 |
| Amurwon, J | 2 |
| Wakholi, BN | 2 |
| Whitworth, J | 1 |
| Wangati, K | 1 |
| Amuron, B | 1 |
| Kajungu, D | 1 |
| Nakiyingi, J | 1 |
| Omony, W | 1 |
| Tumukunde, D | 1 |
| Otim, T | 1 |
| Kabanda, J | 1 |
| Musana, H | 1 |
| Akao, J | 1 |
| Kyomugisha, H | 1 |
| Byamukama, A | 1 |
| Sabiiti, J | 1 |
| Komugyena, J | 1 |
| Wavamunno, P | 1 |
| Mukiibi, S | 1 |
| Drasiku, A | 1 |
| Byaruhanga, R | 1 |
| Labeja, O | 1 |
| Katundu, P | 3 |
| Tugume, S | 2 |
| Awio, P | 1 |
| Namazzi, A | 1 |
| Bakeinyaga, GT | 1 |
| Katabira, H | 1 |
| Abaine, D | 1 |
| Tukamushaba, J | 1 |
| Anywar, W | 1 |
| Ojiambo, W | 1 |
| Angweng, E | 1 |
| Murungi, S | 2 |
| Haguma, W | 1 |
| Atwiine, S | 1 |
| Kigozi, J | 3 |
| Namale, L | 1 |
| Mukose, A | 1 |
| Mulindwa, G | 1 |
| Atwiine, D | 1 |
| Muhwezi, A | 1 |
| Nimwesiga, E | 1 |
| Barungi, G | 1 |
| Takubwa, J | 1 |
| Mwebesa, D | 1 |
| Kagina, G | 1 |
| Mulindwa, M | 1 |
| Ahimbisibwe, F | 1 |
| Mwesigwa, P | 1 |
| Akuma, S | 1 |
| Zawedde, C | 1 |
| Nyiraguhirwa, D | 1 |
| Tumusiime, C | 1 |
| Bagaya, L | 1 |
| Namara, W | 1 |
| Karungi, J | 1 |
| Kankunda, R | 1 |
| Enzama, R | 1 |
| Latif, A | 2 |
| Robertson, V | 2 |
| Chidziva, E | 1 |
| Bulaya-Tembo, R | 1 |
| Musoro, G | 1 |
| Taziwa, F | 1 |
| Chimbetete, C | 1 |
| Chakonza, L | 1 |
| Mawora, A | 1 |
| Muvirimi, C | 1 |
| Tinago, G | 1 |
| Svovanapasis, P | 1 |
| Simango, M | 1 |
| Chirema, O | 1 |
| Machingura, J | 1 |
| Mutsai, S | 1 |
| Phiri, M | 1 |
| Bafana, T | 1 |
| Chirara, M | 2 |
| Muchabaiwa, L | 2 |
| Muzambi, M | 2 |
| Mutowo, J | 1 |
| Chivhunga, T | 1 |
| Chigwedere, E | 1 |
| Pascoe, M | 1 |
| Warambwa, C | 1 |
| Zengeza, E | 1 |
| Mapinge, F | 1 |
| Makota, S | 1 |
| Jamu, A | 1 |
| Ngorima, N | 1 |
| Chirairo, H | 1 |
| Chitsungo, S | 1 |
| Chimanzi, J | 1 |
| Maweni, C | 1 |
| Warara, R | 1 |
| Matongo, M | 1 |
| Mudzingwa, S | 1 |
| Jangano, M | 1 |
| Moyo, K | 1 |
| Vere, L | 1 |
| Mdege, N | 1 |
| Machingura, I | 1 |
| Ronald, A | 1 |
| Kambungu, A | 1 |
| Lutwama, F | 1 |
| Mambule, I | 1 |
| Nanfuka, A | 1 |
| Walusimbi, J | 1 |
| Nabankema, E | 1 |
| Nalumenya, R | 1 |
| Namuli, T | 1 |
| Kulume, R | 1 |
| Namata, I | 1 |
| Nyachwo, L | 1 |
| Florence, A | 1 |
| Kusiima, A | 1 |
| Lubwama, E | 1 |
| Nairuba, R | 1 |
| Oketta, F | 1 |
| Buluma, E | 1 |
| Waita, R | 1 |
| Ojiambo, H | 1 |
| Sadik, F | 1 |
| Wanyama, J | 1 |
| Nabongo, P | 1 |
| Oyugi, J | 1 |
| Sematala, F | 1 |
| Muganzi, A | 1 |
| Twijukye, C | 1 |
| Byakwaga, H | 1 |
| Ochai, R | 1 |
| Muhweezi, D | 1 |
| Coutinho, A | 1 |
| Etukoit, B | 1 |
| Gilks, C | 2 |
| Boocock, K | 1 |
| Puddephatt, C | 1 |
| Grundy, C | 1 |
| Bohannon, J | 1 |
| Winogron, D | 1 |
| Burke, A | 1 |
| Babiker, A | 2 |
| Wilkes, H | 1 |
| Rauchenberger, M | 1 |
| Sheehan, S | 1 |
| Spencer-Drake, C | 1 |
| Taylor, K | 1 |
| Spyer, M | 1 |
| Ferrier, A | 1 |
| Naidoo, B | 1 |
| Dunn, D | 2 |
| Goodall, R | 2 |
| Peto, L | 1 |
| Nanfuka, R | 1 |
| Mufuka-Kapuya, C | 1 |
| Pillay, D | 1 |
| McCormick, A | 1 |
| Weller, I | 1 |
| Bahendeka, S | 1 |
| Bassett, M | 1 |
| Wapakhabulo, AC | 1 |
| Gazzard, B | 1 |
| Mapuchere, C | 1 |
| Mugurungi, O | 1 |
| Burke, C | 1 |
| Jones, S | 1 |
| Newland, C | 1 |
| Pearce, G | 1 |
| Rahim, S | 1 |
| Rooney, J | 1 |
| Smith, M | 1 |
| Snowden, W | 1 |
| Steens, JM | 1 |
| Breckenridge, A | 1 |
| McLaren, A | 1 |
| Hill, C | 1 |
| Matenga, J | 1 |
| Pozniak, A | 1 |
| Serwadda, D | 1 |
| Peto, T | 1 |
| Palfreeman, A | 1 |
| Borok, M | 1 |
| Anwikar, SR | 1 |
| Bandekar, MS | 1 |
| Smrati, B | 1 |
| Pazare, AP | 1 |
| Tatke, PA | 1 |
| Kshirsagar, NA | 1 |
| Aizire, J | 1 |
| Fowler, MG | 1 |
| Wang, J | 1 |
| Shetty, AK | 1 |
| Stranix-Chibanda, L | 1 |
| Kamateeka, M | 1 |
| Brown, ER | 1 |
| Bolton, SG | 1 |
| Musoke, PM | 1 |
| Coovadia, H | 1 |
| Nyesigire Ruhinda, E | 1 |
| Bajunirwe, F | 1 |
| Kiwanuka, J | 1 |
| Taha, TE | 1 |
| Kumwenda, N | 1 |
| Kafulafula, G | 1 |
| Kumwenda, J | 1 |
| Chitale, R | 1 |
| Nkhoma, C | 1 |
| Mukiibi, J | 1 |
| Chen, S | 1 |
| Hoover, D | 1 |
| Broadhead, R | 1 |
| Thorne, C | 1 |
| Jamisse, L | 1 |
| Balkus, J | 1 |
| Hitti, J | 1 |
| Gloyd, S | 1 |
| Manuel, R | 1 |
| Osman, N | 1 |
| Djedje, M | 1 |
| Farquhar, C | 1 |
| Laurent, C | 1 |
| Bourgeois, A | 1 |
| Mpoudi-Ngolé, E | 1 |
| Kouanfack, C | 1 |
| Mougnutou, R | 1 |
| Nkoué, N | 1 |
| Koulla-Shiro, S | 1 |
| Delaporte, E | 1 |
| Kumarasamy, N | 1 |
| Venkatesh, KK | 1 |
| Cecelia, AJ | 1 |
| Devaleenal, B | 1 |
| Lai, AR | 1 |
| Saghayam, S | 1 |
| Balakrishnan, P | 1 |
| Yepthomi, T | 1 |
| Poongulali, S | 1 |
| Flanigan, TP | 1 |
| Solomon, S | 1 |
| Mayer, KH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Intermittent Preventive Treatment (IPTp) With Sulfadoxine-Pyrimethamine Plus Insecticide Treated Nets, Delivered Through Antenatal Clinics for the Prevention of Malaria in Mozambican Pregnant Women[NCT00209781] | 1,028 participants | Interventional | 2003-08-31 | Active, not recruiting | |||
| A Phase III Trial to Determine the Efficacy and Safety of an Extended Regimen of Nevirapine in Infants Born to HIV-Infected Women to Prevent Vertical HIV Transmission During Breastfeeding[NCT00074412] | Phase 3 | 2,026 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| A Phase I Study of the Safety, Tolerance, and Pharmacokinetics of Tenofovir Disoproxil Fumarate (TDF) and the Combination of TDF Plus Emtricitabine in HIV-1 Infected Pregnant Women and Their Infants[NCT00076791] | Phase 1 | 66 participants (Actual) | Interventional | 2004-03-31 | Completed | ||
| Phase II Study of the Pharmacokinetics of Nevirapine and the Incidence of Nevirapine Resistance Mutations in HIV-Infected Women Receiving a Single Intrapartum Dose of Nevirapine With the Concomitant Administration of Zidovudine/Didanosine or Zidovudine/Di[NCT00109590] | Phase 2 | 175 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
For those infants who were randomized at 6 weeks and who initiated study drug we looked at the frequency and severity of adverse reactions through 18 months of study. The severity of all AEs was graded according to the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events. The term severity is described as the intensity grade or level for specific event (i.e. mild, moderate, severe, or life-threatening). Severity is not the same as seriousness. (NCT00074412)
Timeframe: 6 weeks through 18 months
| Intervention | Number of Adverse Events (Number) | ||||
|---|---|---|---|---|---|
| Death | Life-Threatening | Severe | Moderate | Mild | |
| Nevirapine | 26 | 87 | 375 | 694 | 832 |
| Placebo | 30 | 87 | 332 | 677 | 838 |
(NCT00074412)
Timeframe: At Month 6
| Intervention | participants (Number) | |
|---|---|---|
| # of HIV infections at 6 months | # of Infants at risk for HIV infection at 6 months | |
| Nevirapine | 8 | 700 |
| Placebo | 18 | 699 |
(NCT00074412)
Timeframe: At Month 18
| Intervention | participants (Number) | |
|---|---|---|
| # Infant Deaths at 18 months | # Infants at risk of death at 18 months | |
| Nevirapine | 26 | 678 |
| Placebo | 30 | 684 |
(NCT00074412)
Timeframe: At Months 6 and 18
| Intervention | participants (Number) | |
|---|---|---|
| Number of Infants Alive and HIV-free at 6 months | Number of Infants Alive and HIV-free at 18 months | |
| Nevirapine | 689 | 629 |
| Placebo | 683 | 616 |
(NCT00074412)
Timeframe: At Month 18
| Intervention | participants (Number) | |
|---|---|---|
| # of infants with HIV infection at 18 months | # of infants @ risk for HIV infection at 18 months | |
| Nevirapine | 16 | 664 |
| Placebo | 23 | 663 |
Data was analyzed with WinNonLin (Version 5.2, Pharsight, USA) using non-compartmental methods. The pharmacokinetic parameters were calculated using the linear-trapezoidal rule. Cpredose and C4hour at the two measurement times were compared within-subject using the Wilcoxon signed-rank test. (NCT00109590)
Timeframe: Within 72 hours postpartum and during the first 30 days postpartum
| Intervention | ug*hr/mL (Median) |
|---|---|
| Within 72 Hrs Ppm | 99.7 |
| At Day 30 Ppm | NA |
Data was analyzed with WinNonLin (Version 5.2, Pharsight, USA) using non-compartmental methods. The pharmacokinetic parameters were calculated using the linear-trapezoidal rule. Cpredose and C4hour at the two measurement times were compared within-subject using the Wilcoxon signed-rank test. (NCT00109590)
Timeframe: Within 72 hours postpartum and during the first 30 days postpartum
| Intervention | ug/mL (Median) |
|---|---|
| Within 72 Hrs Ppm | 10.78 |
| At Day 30 Ppm | 12.96 |
Data was analyzed with WinNonLin (Version 5.2, Pharsight, USA) using non-compartmental methods. The pharmacokinetic parameters were calculated using the linear-trapezoidal rule. Cpredose and C4hour at the two measurement times were compared within-subject using the Wilcoxon signed-rank test. (NCT00109590)
Timeframe: Within 72 hours postpartum and during the first 30 days postpartum
| Intervention | ug/mL (Median) |
|---|---|
| Within 72 Hrs Ppm | 11.2 |
| At Day 30 Ppm | NA |
(NCT00109590)
Timeframe: at 24 weeks postpartum
| Intervention | log10 copies/mL (Median) |
|---|---|
| Arm A : LPV/r x 7d | 4.3 |
| Arm B : no LPV/r | 3.9 |
| Arm C: LPV/r x 30d | 4.0 |
Adverse events were graded using the Division of AIDS (DAIDS) Table for Grading > the Severity of Adult and Pediatric Adverse Events (December 2004). All grade 3 and higher signs, symptoms, and laboratory toxicities (and events of any grade that led to a change in study treatment) were included. (NCT00109590)
Timeframe: After start of study Treatment (postpartum)
| Intervention | participants (Number) |
|---|---|
| Arm A : LPV/r x 7d | 2 |
| Arm B : no LPV/r | 0 |
| Arm C: LPV/r x 30d | 2 |
Data was analyzed with WinNonLin (Version 5.2, Pharsight, USA) using non-compartmental methods. The pharmacokinetic parameters were calculated using the linear-trapezoidal rule. Cpredose and C4hour at the two measurement times were compared within-subject using the Wilcoxon signed-rank test. (NCT00109590)
Timeframe: Within 72 hours postpartum and during the first 30 days postpartum
| Intervention | ug/mL (Median) |
|---|---|
| Within 72 Hrs Ppm | 6.08 |
| At Day 30 Ppm | 9.17 |
Resistance mutations as identified by consensus sequencing or OLA (NCT00109590)
Timeframe: 24 weeks postpartum
| Intervention | participants (Number) |
|---|---|
| Arm B : no LPV/r | 0 |
| Arm C: LPV/r x 30d | 0 |
The incidence of new NVP resistance mutations at day 10 or week 6 postpartum in each randomized arm. Samples with viral load <500 copies/mL were considered free of mutations. If a resistance result was missing for reasons other than VL <500 copies/ml it was conservatively imputed as resistant in the primary analysis. (NCT00109590)
Timeframe: at Day 10 or Week 6 postpartum.
| Intervention | percent of participants (Number) |
|---|---|
| Arm A : LPV/r x 7d | 3.6 |
| Arm B : no LPV/r | 7.1 |
| Arm C : LPV/r x 30d | 5.3 |
The incidence of new NVP resistance mutations at day 10 or week 6 postpartum in each randomized arm. Samples with viral load <500 copies/mL were considered free of mutations. If a resistance result was missing for reasons other than VL <500 copies/ml it was conservatively imputed as resistant in the primary analysis. (NCT00109590)
Timeframe: at Day 10 or Week 6 postpartum.
| Intervention | percent of participants (Number) |
|---|---|
| Arm A: LPV/r x 7d | 4.9 |
| Arm B: no LPV/r | 9.5 |
| Arm C : LPV/r x 30d | 7.0 |
The incidence of new NVP resistance mutation in plasma HIV within 8 weeks postpartum in each randomized arm was estimated using an exact binomial confidence interval. If a resistance mutation was detected at any of the timepoints then an endpoint was met. Samples with VL <500 copies/mL were considered free of mutations. If a resistance result was missing for reasons other than VL <500 copies/ml (e.g.missed visit), it was conservatively imputed as resistant in the primary analysis. (NCT00109590)
Timeframe: within 8 weeks postpartum.
| Intervention | percent of participants (Number) |
|---|---|
| Arm A : LPV/r x 7d | 7.1 |
| Arm B : no LPV/r | 12.5 |
| Arm C: LPV/r x 30d | 5.3 |
Resistance mutations as identified by OLA in plasma samples or PBMC at 72 weeks postpartum amongst women who had new NVP resistance mutations within 8 weeks postpatrum. These results were based on the 13 women who developed a new NVP resistance mutation in the first 8 weeks postpartum. For the primary outcome measure 1, one particpant in arm A was unavailable for follow-up after week 5 and was conservatively imputed to have developed resistance mutation. (NCT00109590)
Timeframe: within 72 weeks postpartum
| Intervention | participants (Number) | |
|---|---|---|
| OLA in plasma samples | OLA in PBMC | |
| Arm A : LPV/r x 7d | 0 | 0 |
| Arm B : no LPV/r | 0 | 0 |
| Arm C: LPV/r x 30d | 0 | 1 |
(NCT00109590)
Timeframe: At Week 5 postpartum (ZDV) and at the first timepoint with viral load >=500 copies/ml after treatment discontinuation (ddI and LPV/r).
| Intervention | percent of participants (Number) | ||
|---|---|---|---|
| The proportion of women with new ZDV resistance | The proportion of women with new ddI resistance | The proportion of women with new LPV/r resistance | |
| Arm A : LPV/r x 7d | 0 | 0 | 0 |
| Arm B : no LPV/r | 1.78 | 0 | 0 |
| Arm C: LPV/r x 30d | 0 | 0 | 0 |
1 review available for nevirapine and Anemia
| Article | Year |
|---|---|
The safety of antiretroviral drugs in pregnancy.
Topics: Abnormalities, Drug-Induced; Acidosis, Lactic; Anemia; Animals; Anti-Retroviral Agents; Chemical and | 2005 |
The safety of antiretroviral drugs in pregnancy.
Topics: Abnormalities, Drug-Induced; Acidosis, Lactic; Anemia; Animals; Anti-Retroviral Agents; Chemical and | 2005 |
The safety of antiretroviral drugs in pregnancy.
Topics: Abnormalities, Drug-Induced; Acidosis, Lactic; Anemia; Animals; Anti-Retroviral Agents; Chemical and | 2005 |
The safety of antiretroviral drugs in pregnancy.
Topics: Abnormalities, Drug-Induced; Acidosis, Lactic; Anemia; Animals; Anti-Retroviral Agents; Chemical and | 2005 |
9 trials available for nevirapine and Anemia
| Article | Year |
|---|---|
Maternal anaemia and duration of zidovudine in antiretroviral regimens for preventing mother-to-child transmission: a randomized trial in three African countries.
Topics: Adult; Africa South of the Sahara; Anemia; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; I | 2013 |
Safety of zidovudine dose reduction in treatment-naïve HIV infected patients. A randomized controlled study (MiniZID).
Topics: Adult; Anemia; Anti-HIV Agents; Cameroon; Dose-Response Relationship, Drug; Drug Therapy, Combinatio | 2016 |
Mother-to-child transmission of HIV-1: association with malaria prevention, anaemia and placental malaria.
Topics: Adult; Anemia; Anti-HIV Agents; Antimalarials; CD4 Lymphocyte Count; Drug Combinations; Female; HIV | 2008 |
Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Africa; Aged; Anemia; Anti-Retroviral Agents; CD4 Lymphocyte Count; Crea | 2010 |
Extended prophylaxis with nevirapine and cotrimoxazole among HIV-exposed uninfected infants is well tolerated.
Topics: Adult; Anemia; Anti-HIV Agents; Blotting, Western; Breast Feeding; Drug Administration Schedule; Dru | 2012 |
Anaemia in HIV-infected children: severity, types and effect on response to HAART.
Topics: Adolescent; Anemia; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child; Child, Preschool; | 2012 |
Haematological changes in African children who received short-term prophylaxis with nevirapine and zidovudine at birth.
Topics: Agranulocytosis; Anemia; Anti-HIV Agents; Blood Cell Count; Drug Therapy, Combination; Female; Hemat | 2004 |
Antiretroviral-associated toxicity among HIV-1-seropositive pregnant women in Mozambique receiving nevirapine-based regimens.
Topics: Adult; Alanine Transaminase; Anemia; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Asparta | 2007 |
Tolerability and effectiveness of first-line regimens combining nevirapine and lamivudine plus zidovudine or stavudine in Cameroon.
Topics: Adult; Anemia; Anti-HIV Agents; Cameroon; CD4 Lymphocyte Count; Cohort Studies; Drug Therapy, Combin | 2008 |
6 other studies available for nevirapine and Anemia
| Article | Year |
|---|---|
A Retrospective Review of Serious Adverse Drug Reaction Reports in the Nigerian VigiFlow Database from September 2004 to December 2016.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Anemia; Anti-HIV Agents; Anti-Retroviral Agent | 2019 |
Anemia and risk factors in HAART naïve and HAART experienced HIV positive persons in south west Ethiopia: a comparative study.
Topics: Adolescent; Adult; Anemia; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Child; Child | 2013 |
Serious adverse events are uncommon with combination neonatal antiretroviral prophylaxis: a retrospective case review.
Topics: Anemia; Anti-HIV Agents; Drug Therapy, Combination; Female; Humans; Infant; Infant, Newborn; Infecti | 2015 |
Two for the price of one.
Topics: Adult; Anemia; Anti-HIV Agents; Contraceptive Agents, Female; Drug Therapy, Combination; Endometrios | 2008 |
HAART induced adverse drug reactions: a retrospective analysis at a tertiary referral health care center in India.
Topics: Alkynes; Anemia; Antiretroviral Therapy, Highly Active; Benzoxazines; Chemical and Drug Induced Live | 2011 |
Spectrum of adverse events after generic HAART in southern Indian HIV-infected patients.
Topics: Adult; Anemia; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Chemica | 2008 |